Table 1.
Characteristics of the included studies in the systematic review.
| Study | Country | Study design | Nr. of patients | Histotype | Follow-up time | Male N (%) | Age cut-off (years) |
Older
N (%) |
Na level cut-off (mmol/L) | Hyponatremia N (%) |
|---|---|---|---|---|---|---|---|---|---|---|
| Yang et al. (27) | China | Retrospective | 320 | SCLC | 40 weeks | 219 (68.4%) | 60 | 222 (69.4%) | 135 | 149 (46.6%) |
| Osterlind et al. (28) | Denmark | Retrospective | 815 | SCLC | 18–54 weeks | 584 (71.7%) | 60 | 428 (52.5%) | 136 | 204 (25.0%) |
| Zarzecka et al. (29) | Poland | Retrospective | 290 | NSCLC | NR | 205 (70.7%) | NR | NR | 135 | 47 (16.2%) |
| Hermes et al. (30) | Germany | Retrospective | 395 | SCLC | NR | 240 (60.8%) | 60 | 260 (65.8%) | 135 | 75 (19.0%) |
| Wang et al. (31) | China | Retrospective | 631 | SCLC | NR | 475 (75.3%) | 65 | 91 (14.4%) | 135 | 66 (10.5%) |
| Berardi et al. (32) | Italy | Retrospective | 433 | NSCLC | NR | 299 (69.1%) | NR | NR | 135 | 69 (15.9%) |
| Sengupta et al. (33) | India | Retrospective | 116 | NSCLC +SCLC |
NR | 83 (71.6%) | NR | NR | 135 |
45 (45.5%)
7 (41.2%) |
| Kobayashi et al. (34) | Japan | Retrospective | 386 | NSCLC | 41.2 months | 259 (67.1%) | NR | NR | 139 | 123 (31.9%) |
| Fucá et al. (35) | Italy | Prospective | 197 | NSCLC | 25.7 months | 120 (60.9%) | 65 | 113 (57.4%) | 135 | 26 (13.2%) |
| Alamoudi (36) | Saudi Arabia | Prospective | 114 | SCLC +NSCLC |
NR | 89 (78.1%) | NR | NR | 130 | 64 (56.1%) |
| Hansen et al. (37) | Denmark | Retrospective | 453 | SCLC | 60 months | 243 (53.6%) | 60 | 323 (71.3%) | 135 | 198 (44%) |
| Svaton et al. (38) | Czech Republic | Retrospective | 544 | NSCLC | 84 months | 343 (63.1%) | 65 | 242 (44.5%) | 136 | 117 (21.5%) |
| Allan et al. (39) | U.K. | Retrospective | 411 | SCLC | NR | NR | 65 | 120 (29.2%) | 135 | 111 (27.0%) |
| Li et al. (40) | China | Retrospective | 1083 | NSCLC | 40.84 months | 757 (69.9%) | 65 | 295 (27.2%) | 141,9 | 165 (15.2%) |
| Osterlind et al. (41) | Denmark | Retrospective | 874 | SCLC | 18 months | 631 (72.2%) | 60 | 450 (51.5%) | 136 | 213 (24.4%) |
| Doshi et al. (42) | India | Retrospective | 257 | NSCLC | NR | 180 (70.0%) | NR | NR | 136 | 120 (46.7%) |
| Johnson et al. (43) | U.S.A. | Prospective | 50 | SCLC +NSCLC |
NR | 33 (66.0%) | NR | NR | 130 |
10 (32.3%)
1 (5.3%) |
| Sagman et al. (44) | Canada | Retrospective | 614 | SCLC | NR | 436 (71.0%) | 70 | 88 (14.3%) | 135 | 142 (23.1%) |
| Jacot et al. (45) | France | Retrospective | 301 | NSCLC | 20.8 months | 242 (80.4%) | NR | NR | NR | 24 (8.0%) |
| Hong et al. (46) | China | Retrospective | 999 | SCLC | 10.6 months | 692 (69.3%) | 60 | 387 (38.7%) | 135 | 163 (29.5%) |
| Maestu et al. (47) | Spain | Retrospective | 341 | SCLC | NR | 336 (98.5%) | 65 | 88 (25.8%) | 135 | 10 (3%) |
| Kawahara et al. (48) | Japan | Retrospective | 286 | SCLC | NR | 233 (81.5%) | 66 | 113 (39.5%) | 136 | 40 (14.0%) |
| Cerny et al. (49) | U.K. | Retrospective | 407 | SCLC | NR | 262 (64.4%) | NR | NR | 132 | 53 (13.0%) |
| Ma et al. (50) | China | Retrospective | 158 | SCLC | NR | 135 (85.4%) | 60 | 61 (38.6%) | 135 | 67 (42.4%) |
| Umemura et al. (51) | Japan | Retrospective | 163 | SCLC | 36 months | 129 (79.1%) | 70 | 69 (42.3%) | 135 | 22 (13.5%) |
| Jacot et al. (52) | France | Retrospective | 231 | NSCLC | 35 months | 194 (84,0%) | 60 | 104 (45%) | 132 | 219 (94.8%) |
| Rechnitzer et al. (53) | Germany | Prospective | 229 | NSCLC | 42 months | 185 (80.8%) | 63 | 69 (30.1%) | 137.5 | 59 (25,8%) |
| Bose et al. (54) | India | Retrospective | 40 | NSCLC | 6 months | 38 (95%) | NR | NR | 125 | 8 (20%) |
| Rinaldi et al. (55) | Italy and UK | Retrospective | 647 | NSCLC | NR | 440 (68%) | 65 | NR | 135 | 105 (16.2%) |
| Chan et al. (56) | Ireland | Retrospective | 624 | LC | NR | 370 (59.3%) | NR | NR | 135 | 197 (31.6%) |
| Huang et al. (57) | China | Retrospective | 358 | SCLC | NR | 286 (79.9%) | 70 | 49 (13.7%) | 137 | 54 (15.1%) |
SCLC, Small cell lung cancer; NSCLC, Non-small cell lung cancer; RCT, Randomized control trial; U.S.A, United States of America; U.K., United Kingdom; NR, Not reported.